New cancer clinical trial: Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Published on: August 27, 2018 at 12:00PM
Conditions:   Ovarian Cancer;   Ovarian Neoplasms;   Ovarian Carcinosarcoma;   Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Fallopian Tube Cancer;   Fallopian Tube Neoplasms;   Primary Peritoneal Carcinoma;   Primary Peritoneal Serous Adenocarcinoma
Interventions:   Drug: Paclitaxel;   Drug: TAK228
Sponsors:   Imperial College London;   Takeda Pharmaceuticals International, Inc.;   North Eastern Germany Society of Gynaecologic Oncology
Not yet recruiting
https://ift.tt/2whdWNg